Breaking News

Alibaba Raises $8 Billion in Debut Bond Offering
Tweet TWEET

Clinical Study Updates, Milestones Achievements, and Stock Price Movements - Research Report on Johnson & Johnson, Epizyme,

 Clinical Study Updates, Milestones Achievements, and Stock Price Movements -
 Research Report on Johnson & Johnson, Epizyme, Health Management, DENTSPLY,
                              and Charles River

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 10, 2014

NEW YORK, January 10, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Epizyme Inc. (NASDAQ: EPZM), Health Management Associates
Inc. (NYSE: HMA), DENTSPLY International Inc. (NASDAQ: XRAY) and Charles River
Laboratories (NYSE: CRL). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Johnson & Johnson Research Report

On January 7, 2014, Johnson & Johnson's subsidiary, Janssen Research &
Development LLC (Janssen) announced the early stopping of PCYC-112-CA, the
Phase 3 study of IMBRUVICA (ibrutinib) in the treatment of chronic lymphocytic
leukemia and small lymphocytic leukemia (CLL/SLL), based on the recommendation
of an Independent Data Monitoring Committee (IDMC), which concluded that the
study showed significant difference in progression-free survival (PFS) as
compared to the control, the primary endpoint of the study. "We're delighted
with this outcome, and look forward to sharing these results with the
scientific community and Health Authorities," said Peter F. Lebowitz, MD, PhD,
Oncology Therapeutic Area Head at Janssen, "This Phase 3 randomized study
provides a useful head-to-head comparison of single agent ibrutinib versus
ofatumumab, and builds upon the early evidence of clinical benefit observed in
the ibrutinib Phase 2 program." According to Janssen, the IDMC unanimously
recommended stopping the study early based on a planned interim analysis, in
which statistically significant differences in PFS (as assessed by an
independent review committee) and OS were observed. According to the Company,
the IDMC agreed that these results suggest evidence of clinical benefit as
well as tolerable safety profile in patients receiving ibrutinib as compared
to intravenous doses of ofatumumab. The Full Research Report on Johnson &
Johnson - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Epizyme Inc. Research Report

On January 6, 2014, Epizyme Inc. (Epizyme) announced the achievement of the
proof of concept (POC) milestone in the EPZ-5676 DOT1L inhibitor clinical
program, earning a $25 million payment under the Company's collaboration with
Celgene Corporation (Celgene). Epizyme informed that the milestone was
achieved by objective responses in patients with translocations of the MLL
gene (MLL-r). Epizyme said that the patients are currently enrolled in the
fourth dose cohort in the dose escalation stage of the ongoing Phase 1
clinical study and are receiving uninterrupted treatment with EPZ-5676.
Epizyme added that a development candidate milestone has been achieved for one
of the three histone methyltransferase (HMT) targets included in the Company's
collaboration with GlaxoSmithKline (GSK), earning a $4 million payment. Robert
Gould, Ph.D., CEO at Epizyme, said, "We have achieved the proof of concept
milestone for EPZ-5676, our first-in-class DOT1L inhibitor, in our Celgene
collaboration, initiated an ongoing Phase 1 study of EPZ-6438, our
first-in-class EZH2 inhibitor, in our Eisai collaboration, achieved a
Development Candidate milestone in our GSK collaboration, and continue to
advance our pipeline of personalized therapeutics for patients with
genetically defined cancers." The Full Research Report on Epizyme Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/0d2e_EPZM

--

Health Management Associates Inc. Research Report

On January 7, 2014, Health Management Associates Inc.'s (Health Management)
stock rose 1.43%, ending the day's trading at $13.51. Over the previous three
trading sessions, shares of Health Management gained 1.58%, compared to the
S&P 500 Index, which gained 0.32% during the same period. The Full Research
Report on Health Management Associates Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/9ce8_HMA

--

DENTSPLY International Inc. Research Report

On January 7, 2014, DENTSPLY International Inc.'s (DENTSPLY) stock increased
1.54%, ending the day's trading session at $48.64. Over the previous three
trading sessions, shares of DENTSPLY gained 1.42% compared to the Nasdaq
Composite Index, which gained 0.24% during the same period. The Full Research
Report on DENTSPLY International Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/6b01_XRAY

--

Charles River Laboratories Research Report

On January 7, 2014, Charles River Laboratories' (Charles River) stock gained
6.27%, ending the day at $56.30. Over the previous three trading sessions,
shares of Charles River gained 6.47%, compared to the S&P 500 Index, which
gained 0.32% during the same period. The Full Research Report on Charles River
Laboratories - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a37e_CRL

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.